Phuturdex › Diseases › Neurologic Manifestations
Drugs in development · updated 30 October 2026
Neurologic Manifestations: drugs in development
As of 30 October 2026 there are 13 active clinical trials (recruiting or ongoing, phases I–III) on 15 drugs for neurologic Manifestations. 7 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Sepofarsen | II–III | 2 | NCT03913143 |
| TSHA-102 | III | 2 | NCT07480564 |
| GNR-055 | II–III | 1 | NCT05208281 |
| NGN-401 | III | 1 | NCT05898620 |
| 11C-PIB | I | 1 | NCT04263337 |
| [18F] PBR111 | I | 1 | NCT04263337 |
| CHT101 | I | 1 | NCT07496073 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| AtorvastatinLipitor, Atorvaliq® | III | 1 | NCT04904536 |
| IbrutinibPCI 32765, Imbruvica® | I–II | 1 | NCT04446962 |
| LenalidomideRevlimid, lenalinomide | I–II | 1 | NCT04446962 |
| MirtazapineRemeron Soltab®, Remeron® | II | 1 | NCT07430046 |
| 18F-AV-1451[18F] Flortaucipir, Flortaucipir F18 | I | 1 | NCT04263337 |
| DisulfiramAntabuse® | I | 1 | NCT07719127 |
| ModafinilProvigil® | Early I | 1 | NCT01988883 |
| PropranololHemangeol®, Innopran Xl® | Early I | 1 | NCT01988883 |
Sorted by most advanced phase and number of active trials.
All 15 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Pain 75 drugs
- Postoperative pain 50 drugs
- Chronic pain 40 drugs
- Seizures 21 drugs
- Agnosia 19 drugs
- Neuralgia 21 drugs
- Epilepsy 44 drugs
- Emergence delirium 18 drugs
- Alzheimer's disease 157 drugs
- Down syndrome 36 drugs
- Depression 73 drugs
- Headache 12 drugs
Broader categories
- Nervous System Diseases 39 drugs
- Nervous system heredodegenerative disease 3 drugs
- Genetic disease 33 drugs
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities 4 drugs
- Mental disorder 24 drugs
- Nutritional and metabolic diseases 5 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: NLM MeSH; NLM MeSH term: D009461 “Neurologic Manifestations”.